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Abstract 
Introduction: Neurogenic heterotopic ossification (NHO) may occur as a complication of 
traumatic brain injury (TBI). No “gold standard” for treatment exists and the management of 
clinically significant NHO remains variable. Mature NHO results in a variety of complications 
limiting activities of daily living. The effect of the extracorporeal shock wave therapy (ESWT) 
on the range of motion at the hip and knee, and function in patients with TBI with chronic NHO 
was investigated.   
Methods: A series of single-case studies applying ESWT to chronic NHO at the hip or knee of 
11 patients with TBI was undertaken at a specialised rehabilitation hospital. Participants 
received four applications of high-energy EWST delivered to the affected hip or knee over a 
period of eight weeks. Two-weekly follow-up assessments were carried out and final 
assessments were made three months and six months post-intervention. Range of motion 
(ROM) and Functional Reach (FR) or Modified Functional Reach (MFR) were measured.  
Results: The application of high-energy ESWT was associated with significant improvement 
in ROM (flexion) of the NHO-affected knee (Tau=0.833, 95% CI 0.391 to 1.276, P=0.002) and 
significant improvement of FR (Overall Tau 0.486, 95% CI 0.141 to 0.832, P=0.006), but no 
significant improvement in hip ROM or MFR.  
Conclusions:  ESWT is a novel non-invasive therapy that may improve mobility and balance 
of patients with TBI who have chronic NHO. 
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Introduction and Background  
Under certain pathological conditions bone occasionally forms in tissues other than those 
comprising the skeleton. Neurogenic heterotopic ossification (NHO) often follows serious 
brain injuries [1,2].  The prevalence of clinically significant NHO in patients with traumatic brain 
injury (TBI) has been estimated as being between 10% and 23% [2-5]. NHO typically develops 
around large joints such as the hip or knee within two to four months of neurological insult and 
manifests itself clinically as severe pain, swelling, erythema, and warmth [2]. As the bone 
progressively matures it can result in a variety of complications, including decreased range of 
movement (ROM) of affected joints that may greatly limit activities of daily living, thereby 
adversely affecting the quality of life of already physically compromised patients with TBI  [2,6-
10]. Pharmacotherapy to date has not proven to be successful once NHO has formed [11,12], thus 
surgical removal remains the only treatment option for NHO but is extremely invasive and not 
always possible for all TBI patients [13]. The use of extracorporeal shock wave therapy (ESWT) 
as a treatment of NHO following TBI has received only modest attention [14-17], although it has 
been used in the treatment of a range of musculoskeletal conditions for over 20 years with 
virtually no serious side-effects [18-20]. The aim of this study was to investigate the effects of 
ESWT on ROM of the NHO-affected hip and knee joints in patients with TBI. The effects of 
ESWT on pain has been reported in the companion paper. 
 Methods: 
The Human Research Ethics Committees of Loewenstein Rehabilitation Centre, Israel and 
James Cook University Townsville, Australia, Research ID granted ethics approval for this 
study: 0020-13-LOE. The study was also registered at ClinicalTrials.gov Identifier 
NCT02331628. 
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Study design 
A series of single-case research studies was undertaken where participants were assessed for a 
number of physical characteristics on multiple occasions; i.e. pre-, during, and post-
intervention (Table 1). Four baseline assessments were conducted at two-weekly intervals 
followed by four ESWT interventions and the intervention phase assessments, again at two- 
weekly intervals over a period of eight weeks (Table 1). Subsequently, the post-intervention 
phase of four two - weekly follow-up assessments was carried out (Table 1). Final assessments 
were carried out at three and six months post-intervention (Weeks 26 and 38). This study took 
place at Lowenstein Rehabilitation Centre, Israel between October 13th 2014 and February 23rd 
2016. 
 
Insert Table 1 
 
Participants 
Patients with traumatic brain injury (TBI) who met the selection criteria were identified from 
the database of the Loewenstein Rehabilitation Centre, Israel. Inclusion criteria were: aged over 
18 years, traumatic brain injured, diagnosed with NHO around the hip or knee for a period of 
more than one year, and with stable serum alkaline phosphatase (SAP) level at the time of 
recruitment as seen in their hospital notes.. Exclusion criteria were: pregnancy, or suffering 
from rheumatoid arthritis, ankylosing spondylitis or femoral/pelvic fractures at the time of 
recruitment. All participants who met the inclusion criteria were asked to sign the consent form.  
In those cases where the participants had legal guardians and/or were unable to sign, the legal 
guardian provided informed consent. 
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Intervention 
Using the Minispec™ Extracorporeal Shock Wave instrument (Medispec Int. USA) all 
participants received four applications of EWST delivered to the affected hip or knee over a 
period of eight weeks (one dose every two weeks ± 3 days). The patients received 3000 
shocks/treatment as per the manufacturer’s instructions. The energy flux density (EFD) per 
shock was 0.176 mJ/mm2. This dosage is considered as high energy EWST according to the 
Kassel classification (High EFD>0.12mJ/mm2) [21,22]. 
Reporting Adverse Events 
Participants were asked at each assessment if they had any adverse events to report. 
Outcome measures 
The physical characteristics assessed included the ROM of knee flexion and extension, hip 
flexion and extension, hip abduction and adduction, and hip internal and external rotation. The 
knee and hip ROM measurements were performed using a universal goniometer and a 
standardised protocol as described elsewhere [23]. In addition, we assessed the functional reach 
(FR) and modified functional reach (MFR) of participants. The FR characteristic is a clinically 
accessible measure of balance in standing [24], while the MFR test is a reliable measure of sitting 
balance for those individuals unable to stand [25]. Finally, routinely available laboratory data 
for serum alkaline phosphatase (SAP) were also collected to monitor the progression of NHO 
[26]. The reference SAP values can be found elsewhere [27].  
Statistical analysis 
All individual ROM, FR and MFR data were plotted graphically for visual inspection of trends 
within baseline, intervention and post-intervention phases. The individual and overall effect 
size estimates associated with the application of ESWT were calculated using all participants 
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who completed the trial using the non-parametric non-overlap Tau-U method [28]. In particular, 
the Tau-U score represents the percentage of non-overlap between phases or the percentage of 
data showing improvement between phases [28]. Higher Tau-U scores represent greater 
intervention effect while lower Tau-U scores represent an intervention that is less effective. 
The Tau-U method is designed to control for baseline trend and is the preferred method to 
estimate effect sizes when a positive linear trend in therapeutic direction exists in baseline [28]. 
All Tau-U score computations were performed using the Tau-U Calculator (Single Case 
Research, USA). Statistical significance was defined at the conventional 5% level. 
 Results 
Patient characteristics 
Eleven patients with TBI and chronic NHO were recruited; four patients presented with NHO 
in the knee and seven with NHO in the hip (Table 2). Six patients were ambulant with or 
without an aid (Table 2). Patient with TBI were less likely to be females (2/11; 18%), with a 
mean age of 41±14 years and had BMI of 25±4 kg/m2 (Table 2). NHO tended to occur equally 
at both sides; five patients had their right affected side treated and six out of 11 participants 
were treated on their left affected side (Table 2). All participants presented with varying 
degrees of functional and mobility dysfunction (FIM motor score between 13 and 86; Table 2). 
SAP levels remained within normative values [27] during the study (Table 2). 
 
Insert Table 2 
 
Effect of ESWT on Knee Range of Movement (ROM) 
All 4 patients with NHO around the knee completed the intervention phase; however, one 
patient did not complete the post-intervention phase. Based on the visual inspection of 
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individual knee flexion data during the post-intervention phase, knee flexion improved in all 3 
patients who completed the full trial compared to their respective baseline measures (Figure 
1A). The visual inspection of the knee extension data indicates high variability with no obvious 
trend (Figure 1B). Overall Tau score shows that ESWT was associated with significantly 
improved flexion of the knee post-intervention compared to baseline (Tau=0.833, 95% CI 
0.391 to 1.276, P=0.002; Table 3). There was no statistically significant effect associated with 
the application of ESWT on knee extension during the post-intervention phase compared to the 
baseline phase (Tau 0.000, 95% CI -0.442 to 0.442, P=1.000; Table 3). 
 
Insert Figure 1 
 
Insert Table 3 
Effect of ESWT on Hip Range of Movement (ROM) 
Six out of seven patients with NHO at the hip joint completed the intervention phase and post-
intervention phase. Visual inspection of individual hip movement data during the post-
intervention phase showed that the application of ESWT was associated with a trend of 
improved flexion (Figure 2A) and extension (Figure 2B) of the hip compared to their respective 
baseline phase in three patients (cases 7, 8, and 10; Figures 2A and 2B). The visual inspection 
indicates that case 5 had improved hip flexion only post-intervention relative to baseline, and 
case 6 had improved hip extension only post-intervention relative to baseline (Figure 2A and 
2B). No post-intervention trend of improved hip flexion and extension relative to the baseline 
phase was seen in case 1 (Figure 2A and 2B). The post-intervention data were not available for 
case 9 (Figure 2A and 2B). Visual inspection of individual abduction and adduction data was 
not informative (Figures 3A and 3B), however visual inspection of individual data indicates a 
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decreasing trend in hip internal and external rotation during the post-intervention phase 
compared to baseline in all but one patient who completed the full trial (Figure 4A and 4B, 
respectively). Overall Tau scores based on the comparison of the post-intervention and baseline 
data indicate no association of ESWT with hip flexion (Tau 0.193, 95% CI -0.122 to 0.508, 
P=0.230; Table 4), hip extension (Tau 0.206, 95% CI -0.109 to 0.521, P=0.200; Table 4), hip 
abduction (Tau 0.231, 95% CI -0.084 to 0.546, P=0.151; Table 5), and hip adduction (Tau 
0.191, 95% CI -0.124 to 0.506, P=0.235; Table 5). The application of ESWT was associated 
with the post-intervention reduction of hip internal rotation (Overall Tau -0.331, 95% CI -0.646 
to -0.016, P=0.040; Table 6) and hip external rotation (Overall Tau -0.387, 95% CI -0.702 to -
0.072, P=0.016; Table 6) compared to the respective baseline data. This finding was 
individually statistically significant in cases 5 and 6 (Table 6).   
 
Insert Figure 2 
 
Insert Figure 3 
 
Insert Figure 4 
 
Insert Table 4 
 
Insert Table 5 
 
Insert Table 6 
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Effect of ESWT on Functional Reach (FR) and Modified Functional Reach (MFR) 
Five of the six ambulant patients completed the post-intervention FR testing (Table 7). Visual 
inspection of individual FR test results indicates that ESWT was associated with improved 
distance reached in four of five patients who completed the full trial compared to their 
respective baseline phase (cases 1, 2, 3, and 6; Figure 5A). Overall Tau score indicates that 
ESWT was associated with significant post-intervention improvement in FR test results in 
ambulant TBI patients compared to baseline (Overall Tau 0.486, 95% CI 0.141 to 0.832, 
P=0.006; Table 7). 
Visual inspection of the MFR test results was not conclusive (Figure 5B). The patients with 
TBI who were unable to stand did not show any statistically significant change in distance 
reached post-intervention compared to baseline (Overall Tau=0.319, 95% CI -0.123to0.762, 
P=0.157; Table 7). One participant without any voluntary movements (Case 10), was unable 
to perform either the FR or the MFR test. 
 
Insert Figure 5 
 
Insert Table 7 
Adverse effects 
Minor adverse effects of a transient slight increase in pain immediately following treatment 
were reported in two cases.  
 Discussion 
The purpose of this study was to examine the effects of ESWT on the ROM of large joints 
affected by chronic NHO, specifically the knee or hip, in patients following TBI. In addition 
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the effect of ESWT on function was also assessed. The results obtained from this larger study 
support those demonstrated in our previous case report of the effect of ESWT on hip ROM [17], 
and more importantly, provides additional evidence on the effects of ESWT on both hip and 
knee ROM in patients with TBI and chronic NHO. In particular, after the application of ESWT, 
flexion at the affected knee joint showed overall improvement, but not knee extension. In the 
affected hip joint the application of ESWT was not associated with any overall changes in 
flexion, extension, abduction and adduction, although the post-intervention hip rotation 
parameters showed an overall reduction in the range relative to the baseline. The mechanisms 
underlying the differential effects of the ESWT on the knee and hip ROM were not evident in 
the current study. The findings of no or even negative association of ESWT with hip ROM 
may reflect the difficulty of delivering high energy shock-waves to NHO at the hip-joint due 
to the thickness of the overlying tissues, particularly the adductor muscle. In addition the 
quality of the X-rays at the hip did not allow us to focus on the specific bony bridges possibly 
causing wide dissipation of the shock waves. To overcome the barrier of the specific anatomical 
features of the hip region, it might be necessary to apply higher dosages of ESWT to treat NHO 
at the hip joint or to have better defined X-rays or other imaging methods, where specific bony 
bridges may allow more accurate focussing of the shock waves. This issue needs further 
investigation. 
Although a significant overall improvement was seen in functional reach (FR), similar results 
were not obtained for the modified FR, which has been shown to be a reliable measure of sitting 
balance in those patients unable to stand [25]. Visual analysis and the individual Tau scores did 
however indicate possible clinical improvement in two of the three non-ambulant patients who 
completed the trial. 
The limitations of this study include the relatively small number of participants, in particular 
females. Although the male to female ratio is consistent with that commonly found within this 
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patient population, the small number of women does limit the generalizability of this study. 
Furthermore, this study was conducted as a single-case research design in which within-subject 
rather than between-subjects data are compared, e.g. between the two experimental periods [29]. 
Using this design we were able to demonstrate lasting positive effects on post-intervention 
mobility and physical function associated with the application of ESWT in patients with TBI 
with NHO at the hip or knee joints. No “sham” treatment was used because it was not 
considered feasible with this difficult patient group that frequently presents with a profound 
cognitive impairment following TBI such as aggressiveness, impulsivity, forgetfulness, or 
apathy [30].  
 
Conclusions 
The outcomes of this study show lasting improvements in knee flexion following ESWT in 
TBI patients with chronic NHO. Functional improvement, as demonstrated by significant 
overall post-intervention improvement in FR test results in ambulant patients with TBI was 
also noted. Further investigation of ESWT as a therapeutic approach for improving joint 
mobility and function in patients with NHO is warranted. 
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Table 1: Study design.  
Baseline phase Intervention phase (ESWT) Post-intervention phase 
Week 
0 
Week 
2 
Week 
4 
Week 
6 
Week 
8 
Week 
10 
Week 
12 
Week 
14 
Week 
16 
Week 
18 
Week 
20 
Week 
22 
Week 
26 
Week 
38 
ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM 
FR FR FR FR FR FR FR FR FR FR FR FR FR FR 
MFR MFR MFR MFR MFR MFR MFR MFR MFR MFR MFR MFR MFR MFR 
SAP - - - - SAP - - - - - SAP - - 
 
ESWT, Extracorporeal Shock Wave Therapy; ROM, Range of Movement; FR, Functional Reach; MFR, Modified Functional Reach; SAP, serum 
alkaline phosphatase 
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Table 2: Individual characteristics of TBI patients with chronic NHO included in this study 
Case Gender Age (years) Weight (kg) Height (cm) BMI (kg/m2) FIM SAP (U/L)  Affected joint Walking 
B I PI 
1 m 53 85 171 29 79 79 96 96 left hip yes 
2 m 52 85 175 28 66 72 72 57 right knee yes with cane 
3 m 21 60 167 21 83 112 98 n/a left knee yes with cane 
4 m 57 78 174 26 75 107 107 80 left knee yes 
5 m 26 68 168 24 56 156 167 128 left hip no 
6 m 62 95 173 32 86 95 98 117 right hip yes 
7 m 47 74 194 20 51 149 150 165 right hip no 
8 f 23 58 171 20 73 53 n/a n/a right hip yes with crutches 
9 m 35 75 185 22 25 108 111 n/a right hip no 
10 f 44 63 166 23 13 n/a n/a n/a left hip no 
11 m 36 85 189 29 37 115 115 n/a left knee no 
Mean - 41±14 75±12 176±9 25±4 - - - - - - 
 
m, male; f, female; SAP, Serum Alkaline Phosphatase baseline (B), intervention (I), and post-intervention (PI) values; U/L, units per litre; FIM, 
functional independence measure (FIM motor scores range from 13=total dependence) to 91=total independence); n/a, not available.  
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Table 3: Effect of ESWT on Knee Flexion and Extension. 
Case Knee Baseline vs Intervention Baseline vs Post-intervention 
Tau CI 95% P Tau CI 95% P 
2 Flexion 0.625 -0.224 to 1.474 0.149 0.917 0.151 to 1.683 0.019 
3 Flexion -0.250 -1.099 to 0.599 0.564 1.000 0.234 to 1.766 0.011 
4 Flexion -0.188 -1.036 to 0.661 0.665 n/a n/a n/a 
11 Flexion 0.250 -0.599 to 1.099 0.564 0.583 -0.183 to 1.349 0.136 
Overall Flexion 0.109 -0.315 to 0.534 0.613 0.833 0.391 to 1.276 0.002 
2 Extension 0.313 -0.536 to 1.161 0.471 0.125 -0.641 to 0.891 0.749 
3 Extension -0.250 -1.099 to 0.599 0.564 0.167 -0.599 to 0.933 0.670 
4 Extension -0.125 -0.974 to 0.724 0.773 n/a n/a n/a 
11 Extension -0.563 -1.411 to 0.286 0.194 -0.292 -1.058 to 0.474 0.456 
Overall Extension -0.156 -0.581 to 0.268 0.471 0.000 -0.442 to 0.442 1.000 
n/a, not available; Tau, Tau scores; CI 95%, 95% confidence interval; P, P-value 
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Table 4: Effect of ESWT on Hip Flexion and Extension. 
Case Hip Baseline vs Intervention Baseline vs Post-intervention 
Tau CI 95% P Tau CI 95% P 
1 Flexion -0.250 -1.099 to 0.599 0.564 -0.042 -0.808 to 0.724 0.915 
5 Flexion 0.250 -0.599 to 1.099 0.564 0.500 -0.266 to 1.266 0.201 
6 Flexion 0.375 -0.474 to 1.224 0.387 -0.167 -0.933 to 0.599 0.670 
7 Flexion 0.063 -0.786 to 0.911 0.885 0.333 -0.433 to 1.099 0.394 
8 Flexion -0.500 -1.424 to 0.424 0.289 0.200 -0.600 to 1.000 0.624 
9 Flexion 1.000 0.151 to 1.849 0.021 n/a n/a n/a 
10 Flexion 0.375 -0.474 to 1.224 0.387 0.333 -0.433 to 1.099 0.394 
Overall Flexion 0.196 -0.129 to 0.521 0.238 0.193 -0.122 to 0.508 0.230 
1 Extension 0.125 -0.724 to 0.974 0.773 -0.042 -0.808 to 0.724 0.915 
5 Extension -0.500 -1.349 to 0.349 0.248 -0.125 -0.891 to 0.641 0.749 
6 Extension 1.000 0.151 to 1.849 0.021 0.250 -0.516 to 1.016 0.522 
7 Extension 0.375 -0.474 to 1.224 0.387 0.500 -0.266 to 1.266 0.201 
8 Extension -0.250 -1.174 to 0.674 0.596 0.500 -0.300 to 1.300 0.221 
9 Extension 0.750 -0.099 to 1.599 0.083 n/a n/a n/a 
10 Extension -0.250 -1.099 to 0.599 0.564 0.167 -0.599 to 0.933 0.670 
Overall Extension 0.184 -0.141 to 0.509 0.268 0.206 -0.109 to 0.521 0.200 
n/a, not available; Tau, Tau scores; CI 95%, 95% confidence interval; P, P-value 
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Table 5: Effect of ESWT on Hip Abduction and Adduction. 
Case Hip Baseline vs Intervention Baseline vs Post-intervention 
Tau CI 95% P Tau CI 95% P 
1 Abduction -0.188 -1.036 to 0.661 0.665 0.292 -0.474 to 1.058 0.456 
5 Abduction -0.250 -1.099 to 0.599 0.564 -0.583 -1.349 to 0.183 0.136 
6 Abduction 0.500 -0.349 to 1.349 0.248 0.875 0.109 to 1.641 0.025 
7 Abduction 0.063 -0.786 to 0.911 0.885 0.042 -0.724 to 0.808 0.915 
8 Abduction 0.000 -0.924 to 0.924 1.000 0.350 -0.450 to 1.150 0.391 
9 Abduction -0.250 -1.099 to 0.599 0.564 n/a n/a n/a 
10 Abduction 0.875 0.026 to 1.724 0.043 0.417 -0.349 to 1.183 0.286 
Overall Abduction 0.108 -0.217 to 0.433 0.513 0.231 -0.084 to 0.546 0.151 
1 Adduction 0.313 -0.536 to 1.161 0.471 0.292 -0.474 to 1.058 0.456 
5 Adduction 0.125 -0.724 to 0.974 0.773 -0.250 -1.016 to 0.516 0.522 
6 Adduction 0.625 -0.224 to 1.474 0.149 0.500 -0.266 to 1.266 0.201 
7 Adduction -0.500 -1.349 to 0.349 0.248 0.083 -0.683 to 0.849 0.831 
8 Adduction -0.333 -1.257 to 0.591 0.480 0.100 -0.700 to 0.900 0.807 
9 Adduction 0.625 -0.224 to 1.474 0.149 n/a n/a n/a 
10 Adduction -0.375 -1.224 to 0.474 0.387 0.417 -0.349 to 1.183 0.286 
Overall Adduction 0.073 -0.252 to 0.398 0.659 0.191 -0.124 to 0.506 0.235 
n/a, not available; Tau, Tau scores; CI 95%, 95% confidence interval; P, P-value. 
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Table 6: Effect of ESWT on Hip Internal and External Rotation. 
Case Hip Baseline vs Intervention Baseline vs Post-intervention 
Tau CI 95% P Tau CI 95% P 
1 IR 0.438 -0.411 to 1.286 0.312 -0.167 -0.933 to 0.599 0.670 
5 IR -0.688 -1.536 to 0.161 0.112 -0.917 -1.683 to -0.151 0.019 
6 IR -0.625 -1.474 to 0.224 0.149 -0.292 -1.058 to 0.474 0.456 
7 IR -0.375 -1.224 to 0.474 0.387 -0.417 -1.183 to 0.349 0.286 
8 IR 0.250 -0.674 to 1.174 0.596 -0.100 -0.900 to 0.700 0.807 
9 IR 0.500 -0.349 to 1.349 0.248 n/a n/a n/a 
10 IR -0.063 -0.911 to 0.786 0.885 -0.083 -0.849 to 0.683 0.831 
Overall IR -0.084 -0.409 to 0.241 0.611 -0.331 -0.646 to -0.016 0.040 
1 ER -0.500 -1.349 to 0.349 0.248 -0.583 -1.349 to 0.183 0.136 
5 ER -0.625 -1.474 to 0.224 0.149 -0.750 -1.516 to 0.016 0.055 
6 ER -0.250 -1.099 to 0.599 0.564 -1.000 -1.766 to -0.234 0.011 
7 ER 0.750 -0.099 to 1.599 0.083 -0.125 -0.891 to 0.641 0.749 
8 ER -1.000 -1.924 to -0.076 0.034 -0.450 -1.25 to 0.35 0.270 
9 ER -0.813 -1.661 to 0.036 0.061 n/a n/a n/a 
10 ER 0.125 -0.724 to 0.974 0.773 0.583 -0.183 to 1.349 0.136 
Overall ER -0.323 -0.648 to 0.003 0.052 -0.387 -0.702 to -0.072 0.016 
IR, Internal Rotation; ER, External Rotation; n/a, not available; Tau, Tau scores;  
CI 95%, 95% confidence interval; P, P-value 
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Table 7: Effect of ESWT on Functional Reach and Modified Functional Reach. 
Case Test Baseline vs Intervention Baseline vs Post-intervention 
Tau CI 95% P Tau CI 95% P 
1 FR -0.375 -1.224 to 0.474 0.387 0.125 -0.641 to 0.891 0.749 
2 FR 1.375 0.526 to 2.224 0.002 1.250 0.484 to 2.016 0.001 
3 FR 1.000 0.151 to 1.849 0.021 1.000 0.234 to 1.766 0.011 
4 FR 0.125 -0.724 to 0.974 0.773 n/a n/a n/a 
6 FR 0.063 -0.786 to 0.911 0.885 0.083 -0.683 to 0.849 0.831 
8 FR 0.333 -0.591 to 1.257 0.480 -0.050 -0.850 to 0.750 0.903 
Overall FR 0.227 -0.159 to 0.614 0.249 0.486 0.141 to 0.832 0.006 
5 MFR 0.375 -0.474 to 1.224 0.387 0.417 -0.349 to 1.183 0.286 
7 MFR 0.188 -0.661 to 1.036 0.665 0.292 -0.474 to 1.058 0.456 
9 MFR -0.500 -1.349 to 0.349 0.248 n/a n/a n/a 
10 MFR n/a n/a n/a n/a n/a n/a 
11 MFR 0.500 -0.349 to 1.349 0.248 0.250 -0.516 to 1.016 0.522 
Overall MFR 0.141 -0.2837 to 0.565 0.516 0.319 -0.123 to 0.762 0.157 
 
FR, Functional reach; MFR, Modified Functional Reach; n/a, not available;  
Tau, Tau scores; CI 95%, 95% confidence interval; P, P-value 
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Figure 1: Effect of ESWT on Knee Flexion (A) and Extension (B).  
Horizontal axes, time in weeks (weeks 0 to 6, baseline phase; weeks 8 to 14, intervention 
phase; weeks 16 to 38, post-intervention phase; (time-points are not proportional); 
Vertical axes, angle in degrees measured by a universal goniometer. 
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Figure 2: Effect of ESWT on Hip Flexion (A) and Extension (B).  
Horizontal axes, time in weeks (weeks 0 to 6, baseline phase; weeks 8 to 14, intervention phase; 
weeks 16 to 38, post-intervention phase;( time-points are not proportional); Vertical axes, 
angle in degrees as measured by a universal goniometer. 
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Figure 3: Effect of ESWT on Hip Abduction (A) and Adduction (B).  
Horizontal axes, time in weeks (weeks 0 to 6, baseline phase; weeks 8 to 14, intervention phase; 
weeks 16 to 38, post-intervention phase; (time-points not proportional); Vertical axes, angle 
in degrees as measured by a universal goniometer. 
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Figure 4: Effect of ESWT on Hip Internal (A) and External (B) Rotation.  
Horizontal axes, time in weeks (weeks 0 to 6, baseline phase; weeks 8 to 14, intervention phase; 
weeks 16 to 38, post-intervention phase; time-points are not proportional); Vertical axes, angle 
in degrees measured by a universal goniometer. 
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 Figure 5: Effect of ESWT on Functional Reach (A) and Modified Functional Reach (B).Horizontal axes, time in weeks (weeks 0 to 6, baseline 
phase; weeks 8 to 14, intervention phase; weeks 16 to 38, post-intervention phase; time-points are not proportional); Vertical axes, distance in 
cm as measured by FRT in standing. 
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